X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing GLP-1R, glucagon receptor GCGR, and FGF21R, which is investigated for the treatment of obesity and hypertriglyceridemia in New Zealand.
Lead Product(s): DR10624
Therapeutic Area: Nutrition and Weight Loss Product Name: DR10624
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
Under the agreement, Doer Bio will grant BioNTech a worldwide license to utilize one of Doer Bio's innovative discoveries to research, develop, manufacture, and commercialize innovative biotherapeutics against an undisclosed target.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: BioNTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 10, 2023
Details:
DR30303 is a humanized anti-Claudin18.2 heavy chain antibody Fc fusion protein (VHH-Fc) generated via Doer Biologics' proprietary SMART-VHHBody platform.
Lead Product(s): DR30303,Pembrolizumab
Therapeutic Area: Oncology Product Name: DR30303
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: MSD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
